A Phase II Trial of Bryostatin in Combination With Cisplatin in Patients With Recurrent or Persistent Epithelial Ovarian Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bryostatin-1 (Primary) ; Cisplatin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Aug 2013 Biomarkers information updated
- 16 Mar 2010 Actual end date (1 Mar 2010) added as reported by ClinicalTrials.gov record.
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.